A Potential Lifeline: New Preeclampsia Drug Enters Critical Human Trials

MINNEAPOLIS, MN – March 05, 2026 – By Tyler Nguyen

In a significant development for maternal health, DiaMedica Therapeutics has received clearance from Health Canada to begin a Phase 2 clinical trial for its investigational drug, DM199, as a potential treatment for early-onset preeclampsia. The decision provides a crucial green light for a therapy that aims to address one of the most dangerous and underserved complications in pregnancy, a condition for which no approved cure currently exists.

The Minneapolis-based biopharmaceutical company announced it received a No Objection Letter from the Canadian regulatory body, enabling the initiation of a study that will evaluate the safety and efficacy of DM199 in pregnant women diagnosed with the severe condition. The trial, planned to begin in Canada in 2026, marks a pivotal step in the quest to provide a therapeutic option beyond the current standard of care, which is often premature delivery.

The Urgent, Unmet Need in Preeclampsia Care

Preeclampsia is a devastating hypertensive disorder that arises during pregnancy, affecting 3-8% of pregnancies globally and remaining a leading cause of maternal and infant death. It is characterized by high blood pressure and signs of organ damage, typically to the kidneys and liver. When the condition develops before 34 weeks of gestation, it is classified as early-onset preeclampsia—a particularly aggressive form that poses a grave risk to both mother and fetus.

Currently, the only definitive cure for preeclampsia is the delivery of the baby and placenta. This reality places clinicians and families in a heart-wrenching dilemma, forcing them to balance the risks of a premature birth against the dangers of a progressively worsening maternal condition. While medications like magnesium sulfate can prevent seizures and antihypertensives can help manage blood pressure, none can halt or reverse the underlying disease process.

This therapeutic void means that for women with early-onset preeclampsia, prolonging the pregnancy to allow for fetal development is a high-stakes waiting game. The lack of a disease-modifying drug has created a critical unmet medical need, leaving a trail of serious complications, including fetal growth restriction, placental abruption, and long-term cardiovascular issues for the mother.

A Novel Approach to a Complex Disease

DiaMedica’s DM199, also known as rinvecalinase alfa, represents a fundamentally different approach. The drug is a recombinant, or synthetic, form of a naturally occurring human protein called tissue kallikrein-1 (KLK1). This protein plays a vital role in vascular health by promoting the production of nitric oxide and other compounds that help relax blood vessels, reduce blood pressure, and improve blood flow.

Preeclampsia is understood to be a disease of widespread maternal endothelial dysfunction and vasoconstriction, leading to reduced blood flow to the placenta and other organs. The scientific rationale behind DM199 is that by restoring the function of the KLK1 system, it may be possible to counteract this harmful vascular constriction, improve perfusion to the uterus and placenta, and thereby mitigate the disease's progression.

This strategy is not purely theoretical. The company’s move into a formal Phase 2 trial is bolstered by what it calls “encouraging results” from a smaller, investigator-sponsored study conducted in South Africa. According to company reports, that trial demonstrated that DM199 led to dose-dependent reductions in blood pressure and improved uterine artery blood flow in preeclamptic patients. Critically, the study also confirmed that the drug did not cross the placental barrier, a vital safety consideration for any therapeutic administered during pregnancy.

“Health Canada’s authorization to initiate our Phase 2 clinical trial of DM199 in preeclampsia represents an important regulatory milestone for DiaMedica,” said Rick Pauls, President and Chief Executive Officer of DiaMedica Therapeutics, in a statement. “We look forward to continuing our work to bring a clinically meaningful therapeutic option for women suffering from early-onset preeclampsia, a patient population with significant unmet medical need and no currently approved treatment options.”

Navigating a High-Stakes Regulatory Gauntlet

Developing drugs for pregnant women is one of the most challenging areas in pharmaceutical research, fraught with ethical complexities and high regulatory hurdles. Pregnant women have historically been excluded from clinical trials, leading to a profound lack of evidence-based treatments for conditions that uniquely affect them. DiaMedica’s advancement of DM199 into a Phase 2 trial represents a deliberate effort to fill this gap.

The upcoming Canadian trial is designed as an open-label, dose-ranging study for pregnant women diagnosed with early-onset preeclampsia between 24 and 32 weeks of gestation. It will primarily assess the safety and tolerability of three different subcutaneous doses of DM199 administered every three days until delivery. On an exploratory basis, researchers will also monitor key biomarkers associated with the severity of preeclampsia, including changes in uterine artery blood flow, sFlt-1, and placental growth factor (PlGF). These markers could provide early indications of whether the drug is having its intended biological effect.

DiaMedica is pursuing a strategic global rollout, with plans to expand the trial into the United States and the United Kingdom once it secures the necessary regulatory clearances from the FDA and MHRA, respectively. This phased, multi-national approach allows the company to build a robust data package that can satisfy the stringent requirements of different global health authorities.

The journey ahead is long and uncertain, as the vast majority of drugs that enter clinical trials never make it to market. However, for a condition as severe and overlooked as preeclampsia, the initiation of a well-designed trial for a promising new therapy is a major event. For countless families who have faced the uncertainty and fear of a preeclampsia diagnosis, the start of this trial represents a tangible step forward in a field that has been waiting for a breakthrough for far too long.